Matrixyl (topical)
SupplementThe medical score (55) is lower than the community score (72) because clinical studies are small and predominantly sponsored by Sederma [s2, s7], while community users subjectively report positive skin outcomes and regard Matrixyl as a well-established ingredient in recognized products [c1, c2].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Matrixyl (palmitoyl pentapeptide-4) is the best-studied cosmetic signaling peptide, with plausible mechanisms and multiple positive clinical trials — almost all of them sponsored by manufacturer Sederma and conducted in small samples. Measurable wrinkle reduction after 8–12 weeks is realistic, but less pronounced than with retinol. A sensible, well-tolerated alternative to retinol, especially for sensitive skin. Anyone expecting dramatic results will be disappointed.
Description
Matrixyl (Palmitoyl Pentapeptide-4) is a biomimetic signaling peptide used in cosmetics that stimulates fibroblasts to synthesize collagen and reduces wrinkles [s1, s2].
Matrixyl is the trade name for Palmitoyl Pentapeptide-4 (Pal-KTTKS), a synthetic signaling peptide originally identified in 1993 by Katayama et al. at the University of Tennessee as a subfragment of the C-terminal propeptide of type-I procollagen [s1]. The sequence KTTKS (lysine-threonine-threonine-lysine-serine) proved to be the shortest subsequence retaining approximately 80% of the parent fragment's activity in stimulating extracellular matrix production by dermal fibroblasts [s1]. The attached palmitoyl chain (C16 fatty acid) is not merely a branding decision but the critical mechanism for transporting the hydrophilic KTTKS peptide through the stratum corneum into the dermis. Without this modification, unmodified KTTKS is undetectable in any skin layer in in vitro permeation experiments [s3]. Three main generations of Matrixyl products exist today: the original Matrixyl (Palmitoyl Pentapeptide-4), Matrixyl 3000 (combination of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7), and Matrixyl Synthe'6 (Palmitoyl Tripeptide-38) [s5, s6]. Clinical double-blind studies demonstrate significant reductions in wrinkle depth and volume after 2 months of topical application [s5, s7]. The original Matrixyl was tested in a placebo-controlled, double-blind study by Robinson et al. (2005), with statistically significant improvements in wrinkles and fine lines observed versus the vehicle control [s2]. In vitro, Palmitoyl Pentapeptide-4 shows dose-dependent increases in collagen I synthesis of 100–200% in skin explant models [s4]. Matrixyl is generally considered well tolerated; no serious adverse effects have been reported in clinical studies [s2, s8]. The EWG rates Palmitoyl Pentapeptide-3/4 with a safety score of 1 (very safe) [s8].
Legal Status (DE)
Matrixyl (Palmitoyl Pentapeptide-4) is an approved cosmetic ingredient in the EU under EU Cosmetics Regulation (EC) No. 1223/2009 and is listed in the CosIng register [s9, s10]. Cosmetic products in Germany are not subject to marketing authorization but must meet the safety requirements of the EU Cosmetics Regulation [s10]. The product is available over the counter as a cosmetic; it is not classified as a medicinal product [s11].
Mechanism of Action
Matrixyl (Palmitoyl Pentapeptide-4) acts as a matrikine — a peptide physiologically released during collagen degradation that stimulates fibroblasts to repair the extracellular matrix. Synthetic Pal-KTTKS mimics this signal exogenously without requiring actual collagen breakdown [s1, s4]. Mechanistic sequence: 1. The palmitoyl chain [C16] sufficiently increases the peptide's lipophilicity to penetrate the lipid phase of the stratum corneum and reach the papillary dermis, where fibroblasts reside [s3, s4]. Radiolabeled studies confirm that palmitoylated peptides reach the dermis, while unmodified peptides remain superficial [s12]. 2. In the dermis, Pal-KTTKS binds to fibroblast receptors and activates a signaling cascade that upregulates gene expression for several ECM components: collagen types I, III, and IV, fibronectin, hyaluronan synthase-1, and glycosaminoglycans (GAG) [s1, s4, s3]. 3. Additionally, the activity of matrix metalloproteinases (MMPs) that degrade collagen is mildly inhibited [s5]. 4. Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7) acts synergistically: Tripeptide-1 stimulates collagen synthesis, while Tetrapeptide-7 reduces pro-inflammatory cytokines (IL-6) that accelerate skin aging [s5]. 5. Matrixyl Synthe'6 (Palmitoyl Tripeptide-38) stimulates both collagen and elastin synthesis [s6]. The effect is dose-dependent and has been demonstrated in vitro at concentrations of 8–10 ppm in human dermal fibroblasts [s4]. Clinically measurable improvement in skin density and wrinkle reduction typically occurs after 8–12 weeks of regular use, as new collagen fibers require time to form [s12].
Dosing
Faltenreduktion / allgemeine Anti-Aging-Pflege
- Dose
- 0.001–0.005% (equivalent to 10–50 ppm) palmitoyl pentapeptide-4 in the finished formulation
- Frequency
- 1–2× täglich
- Route
- injektion-subkutan
- Duration
- mindestens 8–12 Wochen für messbare Ergebnisse
- Timing
- Morning and/or evening after cleansing, before moisturizer
- With food
- optional
Matrixyl 3000 (Tripeptid-1 + Tetrapeptid-7) – Faltenreduktion
- Dose
- 3% Matrixyl 3000 complex in the formulation (typical market concentration)
- Frequency
- 2× täglich
- Route
- injektion-subkutan
- Duration
- 8 Wochen
- Timing
- Morning and evening
- With food
- optional
Matrixyl Synthe'6 (Palmitoyl Tripeptid-38) – Faltenreduktion
- Dose
- 2% palmitoyl tripeptide-38 in the formulation
- Frequency
- 2× täglich
- Route
- injektion-subkutan
- Duration
- 2 Monate
- Timing
- Morning and evening on affected areas (forehead, eye area)
- With food
- optional
There is no officially established upper limit for Palmitoyl Pentapeptide-4 under the EU Cosmetics Regulation. Studies have used concentrations up to 10 ppm (0.001%) without adverse effects [s2]. Higher concentrations (up to 7% serum) have also been described without adverse effects [s13]; however, long-term safety data for very high concentrations are lacking.
Matrixyl acts slowly (collagen synthesis takes 8–12 weeks); immediate effects are not to be expected [s12]. Combination with retinol or vitamin C is common and mechanistically complementary, though this has been little studied in RCTs to date [c1].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Lokale Hautreizung (Rötung, Brennen) an der Applikationsstelle No irritation was reported in clinical trials [s2, s8]. Rare reactions may be attributable to excipients in the formulation (e.g., preservatives) rather than the peptide itself. | selten | leicht |
| Kontaktallergie / allergische Reaktion No cases documented in clinical studies [s2]. Theoretical risk with peptide hypersensitivity; the palmitic acid component is a common dietary fatty acid and is considered safe [s8]. | theoretisch | moderat |
| Komedogenität (Verstopfen der Poren) Palmitic acid has some comedogenic potential; however, the concentration in the finished product is low. Not explicitly reported in clinical trials [s8]. | theoretisch | leicht |
Contraindications
In documented allergy to the KTTKS sequence or palmitoyl derivatives, the product should not be used. Clinical reports are lacking; caution is warranted [s8].
Cosmetic products are not intended for application on damaged skin. Application to open lesions may cause irritation; the product is formulated for intact skin [s9].
No safety data for pediatric use; cosmetic anti-aging products are designed exclusively for adults [s9].
Interactions
Synergistic
Complementary mechanisms of action: retinol stimulates collagen synthesis via RAR receptors, Matrixyl via matricine signaling pathways. The combination is widely used in the community and mechanistically plausible, however RCTs on the combination are lacking [c1].
Vitamin C is a cofactor of collagen synthesis (prolyl hydroxylase). Combination with Matrixyl is mechanistically rational; no direct RCT evidence for synergism [c1].
Matrixyl stimulates hyaluronan synthase-1; exogenous hyaluronic acid complements this via direct hydration. Frequent combination in serums (e.g., The Ordinary Buffet) [s4, c1].
Argireline relaxes mimetic muscles via inhibition of SNARE proteins, while Matrixyl stimulates collagen synthesis via matricine signaling pathways. The combination simultaneously addresses short-term muscle relaxation and long-term skin renewal. Clinical data from a 2023 study (Li et al., Journal of Cosmetic Dermatology) confirm the tolerability and efficacy of the combination.
GHK-Cu broadly activates fibroblasts (collagen, elastin, glycosaminoglycans) and possesses anti-inflammatory and tissue-remodeling properties, while Matrixyl selectively stimulates collagen synthesis via matrikines. The combination is considered synergistic with complementary targets.
Niacinamide and Matrixyl can be combined without issue. Niacinamide supports the skin barrier and refines pore appearance, while Matrixyl stimulates collagen synthesis — complementary targets with no known adverse interactions.
Caution
Peptides can become unstable and hydrolyze at very low pH. Matrixyl should not be applied simultaneously with strongly acidic actives (e.g., high-concentration AHA/BHA exfoliants) but rather at staggered times [s3].
Peptide instability possible under strongly oxidative or acidic conditions. Staggered application recommended [s3].
At very high concentrations of L-ascorbic acid (above 10%), the acidic environment can destabilize peptides before they penetrate the skin. Stable vitamin C derivatives or staggered application (vitamin C in the morning, Matrixyl in the evening) are advisable.
Retinol and Matrixyl can generally be combined but should be applied at staggered times (e.g., Matrixyl in the morning, retinol in the evening). Simultaneous application carries a risk of skin barrier irritation, particularly at higher retinol concentrations.
Studies
Tier A — High Evidence
Outcome: Quantitative change in periocular wrinkle parameters with 0.005% palmitoyl pentapeptide-4
Effect Size: Significant wrinkle reduction versus placebo (Lintner, 2002; Annales de Dermatologie)
Outcome: Wrinkle reduction on forehead and eye area with 2% palmitoyl tripeptide-38 (Matrixyl Synthe'6)
Effect Size: Significant anti-wrinkle effect; 9% reduction in redness, 8% improvement in skin tone homogeneity
Outcome: Significant reduction in wrinkles and fine lines versus vehicle control, assessed by technical image analysis and expert evaluation
Effect Size: Statistically significant improvement (p-value not extractable from search results); authors: Robinson et al. (2005)
Tier B — Moderate Evidence
Outcome: Periocular wrinkle reduction with 7% Palmitoyl Pentapeptide-4 serum
Effect Size: Positive results (Suhendra, 2020)
Outcome: Reduction of wrinkle depth and volume, and improvement of elasticity and density with 3% Matrixyl 3000
Effect Size: Up to 44% reduction in wrinkle depth after 8 weeks (manufacturer data); 18% reduction in wrinkle depth in a separate study [s5]
Tier C — Low Evidence
Outcome: Dose-dependent stimulation of collagen I synthesis by Pal-KTTKS at 8–10 ppm
Effect Size: 100–200% increase in collagen I synthesis in skin explant models
Outcome: Comparison of dermal stability and skin permeation of KTTKS vs. Palmitoyl-KTTKS; demonstration of the necessity of palmitoylation for skin penetration
Effect Size: Unmodified KTTKS undetectable in any skin layer; Pal-KTTKS reaches the dermis
Community Evidence
Top reported benefits
- Reduction of fine lines and wrinkles after 8–12 weeks
- Improved skin texture and firmness
- Good tolerability, even for sensitive skin
- Gentle alternative to retinol without irritation
- Positive results in combination with hyaluronic acid serums
Top reported issues
- Effect difficult to isolate from other ingredients in combination products
- Results less dramatic than with retinol or professional treatments
- Expensive raw material concentration; budget products often underdosed
- Slow onset of effect; impatience among users
Several community members note that most clinical studies are sponsored by Sederma (the manufacturer) and that sample sizes are small [c1, c3]. The question of whether Matrixyl alone is responsible for results in combination products (e.g., The Ordinary Buffet) remains open [c1]. Some users report that DIY formulations with pure Palmitoyl Pentapeptide-4 may be less effective if pH adjustment or storage is incorrect [c2].
Scientific Sources
- A pentapeptide from type I procollagen promotes extracellular matrix production
Katayama K, Armendariz-Borunda J, Raghow R, et al. (1993). Journal of Biological ChemistryCPMID:8226993DOI - Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products
European Parliament, Council of the European Union (2009). Official Journal of the European UnionALink - Peptide legal in Deutschland? Rechtslage 2026
Peptide Culture Editorial Team (2026). peptide-culture.com (non-peer-reviewed)CLink - Palmitoyl pentapeptide-4: Aesthetics Science & Insights
Creative Touch Rotherham Editorial Team (2024). creativetouchrotherham.co.uk (non-peer-reviewed)CLink - The efficacy of 7% palmitoyl pentapeptide-4 serum for the periorbital area
Suhendra NN (2020). Genevieve.beauty / Lesielle referenceCLink - Palmitoyl pentapeptide provides improvement in photoaged human facial skin
Robinson LR, Fitzgerald NC, Doughty DG, et al. (2005). International Journal of Cosmetic ScienceAPMID:18492182DOI - Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS)
Gorouhi F, Maibach HI (2009). International Journal of DermatologyCDOI - Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety
Peptide Treatments Editorial Team (2024). PeptideTreatments.com (non-peer-reviewed)CLink - Matrixyl 3000: Anti-Falten-Wirkung, Studien & Erfahrungen
Klow Peptide Editorial Team (2026). klow-peptide.com (non-peer-reviewed)CLink - What is Matrixyl Synthe'6 – Anti Wrinkle Ingredient Matrixyl Synthe'6
Truth In Aging Editorial Team (2023). TruthInAging.com (non-peer-reviewed)CLink - Matrixyl Clinical Studies: Anti-Wrinkle Evidence
PeptideJournal Editorial Team (2024). PeptideJournal.org (non-peer-reviewed)CLink - Matrixyl in Hautpflegeseren und -cremes: Funktioniert es?
Baumann L (2024). SkinTypeSolutions.com (non-peer-reviewed)CLink - Safety Assessment of Myristoyl Pentapeptide-4, Palmitoyl Pentapeptide-4 as Used in Cosmetics
Cosmetic Ingredient Review Expert Panel (2023). CIR Safety Assessment (cir-safety.org)ALink
Community Sources
Storage
Unopened
Store cool (15–25 °C), dry, and protected from direct sunlight. Keep in original sealed packaging.
Opened
Use within 6–12 months of opening (observe the PAO indication on the packaging). Close the container tightly after each use.
Notes
Peptides are sensitive to heat, light, and oxidation. Refrigerator temperature (2–8 °C) can extend stability but is not strictly required for most commercial formulations. Pure peptide solutions (DIY) should be stored cool and away from light [s3].